Return on experience from UMCG case mix and ramp-up
Prof. Hans Langendijk shares insights on the first experience with proton therapy at...
Prof. Hans Langendijk shares insights on the first experience with proton therapy at...
Today, 25% of patients that could benefit from proton therapy have moving tumors. However, as treating moving targets with confidence is a challenge, only 1% of...
Do you wonder what it takes to start up a proton therapy center? Would you like to get the latest update on clinical evidence with protons? ESTRO and IBA invite...